DDInter1124 DDInter927
Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Maprotiline {u} (Compound) resembles {v} (Compound) Protriptyline
Maprotiline {u} (Compound) resembles {v} (Compound) Demexiptiline
Maprotiline {u} (Compound) binds {v} (Gene) ABCB1
Maprotiline {u} (Compound) upregulates {v} (Gene) UBE2L6
Maprotiline {u} (Compound) palliates {v} (Disease) panic disorder
Maprotiline {u} (Compound) downregulates {v} (Gene) CCNA2
Maprotiline {u} (Compound) causes {v} (Side Effect) Angiopathy
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ephedrine
Maprotiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Maprotiline (Compound) resembles Protriptyline (Compound)
Maprotiline (Compound) resembles Demexiptiline (Compound)
Maprotiline (Compound) binds ABCB1 (Gene)
Maprotiline (Compound) upregulates UBE2L6 (Gene)
Maprotiline (Compound) palliates panic disorder (Disease)
Maprotiline (Compound) downregulates CCNA2 (Gene)
Maprotiline (Compound) causes Angiopathy (Side Effect)
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Ephedrine
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib